B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cara Therapeutics (NQ: CARA )

0.3111 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cara Therapeutics

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Bullish Tuesday For Marijuana Stocks - Nine Energy Service, ReneSola Among Top Gainers
GAINERS: Nine Energy Service (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Cara Therapeutics To Host Virtual R&D On March 11
Cara Therapeutics, (NASDAQ:CARA) ... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday. Telsey Advisory Group cut Capri... 
Via Benzinga
Looking Into Cara Therapeutics's Return On Capital Employed
Benzinga Pro data, Cara Therapeutics (NASDAQ:CARA) reported Q4 sales of $821.00 thousand. Earnings fell to a loss of $33.38 million, resulting in a 3195.36% decrease from last... 
Via Benzinga
Cara Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results
Cara Therapeutics, Inc. (NASDAQ:CARA), an early commercial... 
Via Benzinga
Recap: Cara Therapeutics Q4 Earnings
Cara Therapeutics (NASDAQ:CARA) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
Cannabis Stock Gainers And Losers From February 2, 2022
GAINERS: Item 9 Labs (OTC:INLB) shares closed up 7.14% at $1.20 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 89 companies hit new 52-week lows. Noteable 52-Week Lows: The company with the largest market cap to set a new 52-week low was Seagen (NASDAQ:SGEN).... 
Via Benzinga
Cannabis Stock Gainers And Losers From January 31, 2022
GAINERS: Greenlane Hldgs (NASDAQ:GNLN) shares closed up 18.20% at $0.76 
Via Benzinga
Cannabis Stock Gainers And Losers From January 27, 2022
GAINERS: MGC Pharmaceuticals (OTC:MGCLF) shares closed up 8.27% at $0.03 
Via Benzinga
Cannabis Stock Gainers And Losers From January 26, 2022
GAINERS: Item 9 Labs (OTC: 
Via Benzinga
Cannabis Stock Gainers And Losers From January 19, 2022
GAINERS: Heritage Cannabis Holding (OTC: 
Via Benzinga
Cannabis Stock Gainers And Losers From January 18, 2022
GAINERS: Item 9 Labs (OTC: 
Via Benzinga
Cannabis Stock Gainers And Losers From January 5, 2022
GAINERS: Rhinomed (OTC: 
Via Benzinga
Cannabis Stock Gainers And Losers From January 3, 2022
GAINERS: BioHarvest Sciences (OTC: 
Via Benzinga
Are Cannabinoids the Next Frontier of Pharmaceuticals? This Company Thinks So and Wants to Lead the Pack
Photo by Michael Longmire on... 
Via Benzinga
XPO Logistics (Formerly Segmentz) Founder and Grove Inc (GRVI) CEO Brings Deep Experience in Growing Companies
Image Provided By Pixabay The following post was... 
Via Benzinga
Cara Therapeutics, inc (CARA) Q3 2021 Earnings Call Transcript
CARA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
3 Explosive Biotech Stocks -- Could They Shoot Even Higher?
These biotech stocks have recently been responsible for a slew of rocketship emojis. 
Via The Motley Fool
Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval
There's good news at long last for the beaten-down biotech stock. 
Via The Motley Fool
Exposures Product Safety
64 Biggest Movers From Yesterday
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Triple-S Management Corporation (NYSE: GTS) shares surged 45.5% to close at $35.20 on Tuesday. GuideWell Mutual Holding Corporation, parent of Blue Cross and Blue Shield... 
Via Benzinga
Why Cara Therapeutics Shot Higher Today
The biotech gets an important nod from a top regulator. 
Via The Motley Fool
Exposures Product Safety
CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing Today
Shares of CARA stock are ticking higher on Tuesday after the Cara Therapeutics' injection treatment was approved by the FDA. 
Via InvestorPlace
Exposures Product Safety
38 Stocks Moving In Tuesday's Mid-Day Session
Gainers Triple-S Management Corporation (NYSE: GTS) shares jumped 45.3% to $35.15. GuideWell Mutual Holding Corporation, parent of Blue Cross and Blue Shield of Florida Inc,... 
Via Benzinga
Why Is Cara Therapeutics Stock Trading Higher Today?
Cara Therapeutics Inc (NASDAQ: CARA) is trading higher Tuesday after the company, and Vifor Pharma, announced the U.S. Food and Drug Administration approved KORSUVA... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.